CY1119897T1 - Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου - Google Patents

Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου

Info

Publication number
CY1119897T1
CY1119897T1 CY20181100151T CY181100151T CY1119897T1 CY 1119897 T1 CY1119897 T1 CY 1119897T1 CY 20181100151 T CY20181100151 T CY 20181100151T CY 181100151 T CY181100151 T CY 181100151T CY 1119897 T1 CY1119897 T1 CY 1119897T1
Authority
CY
Cyprus
Prior art keywords
glycle
adrenomedouline
polythylene
product
prodrugs
Prior art date
Application number
CY20181100151T
Other languages
English (en)
Inventor
Ingo Flamme
Johannes KÖBBERLING
Hans-Georg Lerchen
Nils Griebenow
Rudolf Schohe-Loop
Sven WITTROCK
Maria KÖLLNBERGER
Frank Wunder
Gorden Redlich
Andreas Knorr
July MARLEY
Iain PRITCHARD
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1119897T1 publication Critical patent/CY1119897T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

Η εφεύρεση σχετίζεται με φάρμακα που περιλαμβάνουν νέα πολυαιθυλενο γλυκόλη (PEG), που βασίζεται σε προφάρμακα Αδρενομεδουλλίνης, ή ένα εκ των αλάτων αυτών, επιδιαλυτωμένων συμπλοκών αυτών ή επιδιαλυτωμένων συμπλοκών αλάτων αυτών, σε συνδυασμό με ένα αδρανές μη-τοξικό φαρμακευτικώς κατάλληλο έκδοχο, όπου το φάρμακο υφίσταται σε μία φαρμακευτική μορφή για εισπνοή, την χρήση του για την θεραπευτική αντιμετώπιση και/ή πρόληψη παθήσεων, ειδικότερα καρδιαγγειακών, οιδηματωδών και/ή φλεγμονωδών διαταραχών, σε ειδικά προφάρμακα PEG-αδρενομεδουλλίνης και ενδιαμέσων της σύνθεσης της.
CY20181100151T 2011-11-03 2018-02-07 Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου CY1119897T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03
EP12783566.8A EP2773376B1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof
EP15192265.5A EP3075395B1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof

Publications (1)

Publication Number Publication Date
CY1119897T1 true CY1119897T1 (el) 2018-06-27

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100293T CY1117354T1 (el) 2011-11-03 2016-04-12 Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου
CY20181100151T CY1119897T1 (el) 2011-11-03 2018-02-07 Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100293T CY1117354T1 (el) 2011-11-03 2016-04-12 Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου

Country Status (45)

Country Link
US (3) US9603936B2 (el)
EP (2) EP2773376B1 (el)
JP (2) JP5995984B2 (el)
KR (2) KR101965467B1 (el)
CN (2) CN103998063B (el)
AR (2) AR088582A1 (el)
AU (2) AU2012331244B2 (el)
BR (1) BR112014010708B1 (el)
CA (1) CA2854134C (el)
CL (1) CL2014000948A1 (el)
CO (1) CO7020863A2 (el)
CR (1) CR20140184A (el)
CU (1) CU24184B1 (el)
CY (2) CY1117354T1 (el)
DK (2) DK2773376T3 (el)
DO (2) DOP2014000078A (el)
EA (2) EA025631B1 (el)
EC (2) ECSP14013326A (el)
ES (2) ES2568063T3 (el)
GT (1) GT201400085A (el)
HK (1) HK1246147A1 (el)
HR (2) HRP20160285T1 (el)
HU (2) HUE036535T2 (el)
IL (3) IL232037B (el)
IN (1) IN2014CN03290A (el)
JO (2) JOP20190001B1 (el)
LT (1) LT3075395T (el)
MA (1) MA35618B1 (el)
ME (1) ME02379B (el)
MX (2) MX361287B (el)
MY (2) MY173372A (el)
NO (1) NO3075395T3 (el)
PE (2) PE20141219A1 (el)
PL (2) PL3075395T3 (el)
PT (1) PT3075395T (el)
RS (2) RS54623B1 (el)
SG (2) SG11201400924TA (el)
SI (2) SI2773376T1 (el)
TN (1) TN2014000185A1 (el)
TR (1) TR201802124T4 (el)
TW (2) TWI583396B (el)
UA (1) UA111098C2 (el)
UY (2) UY37922A (el)
WO (1) WO2013064508A1 (el)
ZA (1) ZA201600434B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144705B (zh) * 2011-11-03 2017-03-01 拜耳知识产权有限责任公司 用于肽的可释放性连接的基于酪氨酸的连接体
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
CN106164088B (zh) * 2014-03-20 2021-11-23 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
AU2015323769A1 (en) 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
CN108026182B (zh) 2015-09-18 2022-04-26 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
EP3604538A4 (en) * 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン-類似体およびその使用
JP7498882B2 (ja) * 2019-12-05 2024-06-13 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
IL296972A (en) * 2020-04-03 2022-12-01 Bayer Ag Liquid pharmaceutical formulations of polyethylene glycol-based drug excipients of adrenomedullin and use
WO2021198328A1 (en) 2020-04-03 2021-10-07 Bayer Aktiengesellschaft Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
WO2023021173A1 (en) 2021-08-20 2023-02-23 Bayer Aktiengesellschaft Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7118070B2 (en) 2003-07-23 2006-10-10 Sierracin Corporation Composite seal and window assembly
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
EP1749026B1 (en) 2004-05-24 2011-11-23 Institut de Cardiologie de Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
EP2091570A1 (en) * 2006-12-20 2009-08-26 GE Healthcare AS Contrast agents
WO2008138141A1 (en) * 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
CN104144705B (zh) * 2011-11-03 2017-03-01 拜耳知识产权有限责任公司 用于肽的可释放性连接的基于酪氨酸的连接体

Also Published As

Publication number Publication date
GT201400085A (es) 2015-03-05
TW201332573A (zh) 2013-08-16
CN107412740A (zh) 2017-12-01
HK1246147A1 (zh) 2018-09-07
US9603936B2 (en) 2017-03-28
NZ622997A (en) 2015-12-24
KR20180108892A (ko) 2018-10-04
AU2017203423B2 (en) 2019-01-31
EP3075395A1 (en) 2016-10-05
PT3075395T (pt) 2018-02-13
CA2854134C (en) 2020-04-21
EA201400528A1 (ru) 2014-10-30
IL258229B (en) 2020-02-27
BR112014010708A2 (pt) 2017-04-25
PE20141219A1 (es) 2014-09-13
AU2012331244A1 (en) 2014-04-17
SI2773376T1 (sl) 2016-05-31
UY37922A (es) 2018-11-30
KR101965467B1 (ko) 2019-04-03
DOP2014000078A (es) 2014-07-15
MY173372A (en) 2020-01-21
IL252281A0 (en) 2017-08-31
JO3385B1 (ar) 2019-03-13
TWI653051B (zh) 2019-03-11
ES2659195T3 (es) 2018-03-14
JOP20190001B1 (ar) 2022-03-14
UY34419A (es) 2013-05-31
US20160367636A1 (en) 2016-12-22
IN2014CN03290A (el) 2015-07-03
EA201600495A1 (ru) 2016-10-31
DK2773376T3 (en) 2016-04-18
US9649363B2 (en) 2017-05-16
MX350341B (es) 2017-09-04
ZA201600434B (en) 2017-05-31
TW201720467A (zh) 2017-06-16
AR113830A2 (es) 2020-06-17
ECSP14013326A (es) 2014-05-31
IL258229A (en) 2018-06-28
AU2012331244B2 (en) 2017-06-15
CO7020863A2 (es) 2014-08-11
JOP20190001A1 (ar) 2017-06-16
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
AU2017203423A1 (en) 2017-06-08
TWI583396B (zh) 2017-05-21
CR20140184A (es) 2014-05-27
CN107412740B (zh) 2021-02-09
EA025631B1 (ru) 2017-01-30
JP2017014264A (ja) 2017-01-19
DK3075395T3 (en) 2018-02-19
ECSP18071104A (es) 2018-10-31
HUE027333T2 (en) 2016-09-28
NZ714621A (en) 2017-10-27
SG10201607516SA (en) 2016-10-28
EP3075395B1 (en) 2017-11-22
HUE036535T2 (hu) 2018-07-30
EP2773376A1 (en) 2014-09-10
CU24184B1 (es) 2016-07-29
CN103998063A (zh) 2014-08-20
LT3075395T (lt) 2018-02-26
RS56819B1 (sr) 2018-04-30
US10035818B2 (en) 2018-07-31
SG11201400924TA (en) 2014-09-26
RS54623B1 (en) 2016-08-31
NO3075395T3 (el) 2018-04-21
IL232037A0 (en) 2014-05-28
CN103998063B (zh) 2016-09-21
HRP20180319T1 (hr) 2018-03-23
JP6177975B2 (ja) 2017-08-09
DOP2018000203A (es) 2018-10-15
JP2014532682A (ja) 2014-12-08
EP2773376B1 (en) 2016-01-13
PE20181493A1 (es) 2018-09-18
KR102004668B1 (ko) 2019-07-26
MX2014004384A (es) 2014-04-30
MY194197A (en) 2022-11-21
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
JP5995984B2 (ja) 2016-09-21
US20140287984A1 (en) 2014-09-25
SI3075395T1 (en) 2018-03-30
MA35618B1 (fr) 2014-11-01
CL2014000948A1 (es) 2014-09-05
AR088582A1 (es) 2014-06-18
CY1117354T1 (el) 2017-04-26
IL232037B (en) 2018-12-31
UA111098C2 (uk) 2016-03-25
US20170204137A1 (en) 2017-07-20
ES2568063T3 (es) 2016-04-27
EA029410B1 (ru) 2018-03-30
BR112014010708B1 (pt) 2021-03-02
TR201802124T4 (tr) 2018-03-21
CU20140051A7 (es) 2014-10-02
PL3075395T3 (pl) 2018-04-30
WO2013064508A1 (en) 2013-05-10
PL2773376T3 (pl) 2016-07-29
CA2854134A1 (en) 2013-05-10
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
CY1119897T1 (el) Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1123675T1 (el) Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1122687T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1120452T1 (el) Παραγωγο αμιδιου πυραζολης
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
ECSP17033565A (es) Cromanos sustituidos y métodos para su uso
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
CY1119151T1 (el) Ν-(4-(αζαϊνδαζολ-6-υλ)-φαινυλ)-σουλφοναμιδiα και η χρηση τους ως φαρμακα
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
CY1118323T1 (el) Ρυθμιστες του ηπατικου υποδοχεα χ
DK3935068T3 (da) Abirateron-prodrugs
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1124773T1 (el) Τοπικη φαρμακευτικη συνθεση η οποια εμπεριεχει τουλαχιστον αμιτριπτυλινη για τη θεραπευτικη αντιμετωπιση του περιφερικου νευροπαθητικου αλγους
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA